(19)
(11) EP 3 928 835 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
09.02.2022 Bulletin 2022/06

(43) Date of publication:
29.12.2021 Bulletin 2021/52

(21) Application number: 20861942.9

(22) Date of filing: 17.07.2020
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
A61K 31/496(2006.01)
 A61K 47/60(2017.01)
(86) International application number:
PCT/JP2020/027805
(87) International publication number:
WO 2021/229832 (18.11.2021 Gazette 2021/46)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 14.05.2020 JP 2020084919

(71) Applicant: Delta-Fly Pharma, Inc.
Tokushima-shi Tokushima 771-0116 (JP)

(72) Inventors:
  • ESHIMA, Kiyoshi
    Tokushima-shi, Tokushima 771-0116 (JP)
  • ISHIDA, Tatsuhiro
    Tokushima-shi, Tokushima 770-0806 (JP)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)

   


(54) WATER-SOLUBLE POLYMERIC DERIVATIVE OF VENETOCLAX


(57) The present invention aims at providing novel means for administering Venetoclax, wherein the means reduces the burden on a patient caused by taking Venetoclax and achieves a good balance between the effect and safety of Venetoclax. The present invention relates to a water-soluble macromolecular derivative that includes a plurality of Venetoclaxs, each Venetoclax being linked to a terminal carboxyl group of a multi-arm water-soluble polymer via an amide bond.